CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade BIOLASE - BIOL CFD

4.30
5.07%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.14
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024068%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.001846%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 4.54
Open* 4.38
1-Year Change* 1.62%
Day's Range* 4.26 - 4.58
52 wk Range 0.30-9.24
Average Volume (10 days) 272.89K
Average Volume (3 months) 11.95M
Market Cap 13.04M
P/E Ratio -100.00K
Shares Outstanding 35.58M
Revenue 46.82M
EPS -3.68
Dividend (Yield %) N/A
Beta 1.42
Next Earnings Date Mar 28, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 29, 2022 4.30 -0.08 -1.83% 4.38 4.58 4.22
Jun 28, 2022 4.54 0.32 7.58% 4.22 5.00 4.22
Jun 27, 2022 5.08 0.86 20.38% 4.22 5.19 4.22
Jun 24, 2022 4.47 0.25 5.92% 4.22 4.60 4.22
Jun 23, 2022 4.19 0.12 2.95% 4.07 4.30 4.07
Jun 22, 2022 4.05 -0.27 -6.25% 4.32 4.52 3.99
Jun 21, 2022 4.32 0.04 0.93% 4.28 4.53 4.16
Jun 17, 2022 4.51 0.22 5.13% 4.29 4.51 4.29
Jun 16, 2022 4.17 -0.01 -0.24% 4.18 4.37 4.16
Jun 15, 2022 4.26 0.19 4.67% 4.07 4.26 4.07
Jun 14, 2022 4.26 0.17 4.16% 4.09 4.37 4.09
Jun 13, 2022 4.10 -0.17 -3.98% 4.27 4.34 4.07
Jun 10, 2022 4.56 -0.06 -1.30% 4.62 4.62 4.47
Jun 9, 2022 4.67 0.03 0.65% 4.64 4.76 4.64
Jun 8, 2022 4.63 0.01 0.22% 4.62 4.71 4.59
Jun 7, 2022 4.64 0.02 0.43% 4.62 4.73 4.62
Jun 6, 2022 4.67 0.03 0.65% 4.64 4.79 4.59
Jun 3, 2022 4.82 0.20 4.33% 4.62 4.90 4.62
Jun 2, 2022 4.67 0.04 0.86% 4.63 4.80 4.61
Jun 1, 2022 4.63 -0.15 -3.14% 4.78 4.78 4.57

BIOLASE Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 39.188 22.78 37.799 46.155 46.926
Revenue 39.188 22.78 37.799 46.155 46.926
Cost of Revenue, Total 22.659 16.607 23.511 29.26 31.8
Gross Profit 16.529 6.173 14.288 16.895 15.126
Total Operating Expense 52.605 41.316 53.42 67.04 64.964
Selling/General/Admin. Expenses, Total 26.597 21.014 25.144 29.892 26.43
Research & Development 6.048 3.695 4.765 5.203 6.229
Unusual Expense (Income) -2.699 0 0 2.685 0.505
Operating Income -13.417 -18.536 -15.621 -20.885 -18.038
Interest Income (Expense), Net Non-Operating -2.676 -2.38 -2.278 -0.568 0.605
Net Income Before Taxes -16.093 -16.701 -17.899 -21.453 -17.433
Net Income After Taxes -16.158 -16.829 -17.855 -22.116 4.249
Net Income Before Extra. Items -16.158 -16.829 -17.855 -22.116 4.249
Net Income -16.158 -16.829 -17.855 -21.516 -16.851
Total Adjustments to Net Income -0.546 -17.378 0 0 -3.978
Income Available to Common Excl. Extra. Items -16.704 -34.207 -17.855 -22.116 0.271
Income Available to Common Incl. Extra. Items -16.704 -34.207 -17.855 -21.516 -20.829
Diluted Net Income -16.704 -34.207 -17.855 -21.516 -20.829
Diluted Weighted Average Shares 5.90984 2.44544 0.92804 0.82352 0.59007
Diluted EPS Excluding Extraordinary Items -2.82647 -13.9881 -19.2395 -26.8554 0.45927
Diluted Normalized EPS -3.12332 -13.9881 -19.2395 -24.7362 1.01555
Total Extraordinary Items 0.6 -21.1
Other, Net 0 4.215
Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021
Total revenue 12.01 12.235 10.166 12.408 9.531
Revenue 12.01 12.235 10.166 12.408 9.531
Cost of Revenue, Total 9.565 7.094 5.437 7.502 4.689
Gross Profit 2.445 5.141 4.729 4.906 4.842
Total Operating Expense 19.661 17.29 14.372 16.838 12.188
Selling/General/Admin. Expenses, Total 8.117 8.543 7.391 7.669 5.93
Research & Development 1.979 1.653 1.544 1.542 1.54
Operating Income -7.651 -5.055 -4.206 -4.43 -2.657
Interest Income (Expense), Net Non-Operating -0.753 -0.533 -0.553 -0.777 -0.605
Net Income Before Taxes -8.404 -5.588 -4.759 -5.207 -3.262
Net Income After Taxes -8.387 -5.611 -4.776 -5.279 -3.276
Net Income Before Extra. Items -8.387 -5.611 -4.776 -5.279 -3.276
Net Income -8.387 -5.611 -4.776 -5.279 -3.276
Total Adjustments to Net Income 0 0 -0.217 0 -0.009
Income Available to Common Excl. Extra. Items -8.387 -5.611 -4.993 -5.279 -3.285
Income Available to Common Incl. Extra. Items -8.387 -5.611 -4.993 -5.279 -3.285
Diluted Net Income -8.387 -5.611 -4.993 -5.279 -3.285
Diluted Weighted Average Shares 7.615 6.192 6.159 6.14228 6.07764
Diluted EPS Excluding Extraordinary Items -1.10138 -0.90617 -0.81068 -0.85945 -0.54051
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.10138 -0.90617 -0.81068 -0.84622 -0.5374
Unusual Expense (Income) 0 0 0.125 0.029
Other, Net 0 0
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 49.354 35.11 27.019 33.307 36.05
Cash and Short Term Investments 29.972 17.564 5.789 8.044 11.645
Cash & Equivalents 29.972 17.564 5.789 8.044 11.645
Total Receivables, Net 4.238 3.059 8.76 11.112 10.124
Accounts Receivable - Trade, Net 4.238 3.059 8.76 10.99 10.047
Total Inventory 12.929 11.157 10.995 12.248 12.298
Prepaid Expenses 2.012 3.018 1.163 1.591 1.732
Other Current Assets, Total 0.203 0.312 0.312 0.312 0.251
Total Assets 55.284 41.025 31.847 38.516 42.984
Property/Plant/Equipment, Total - Net 2.784 2.758 1.469 1.975 3.674
Property/Plant/Equipment, Total - Gross 10.833 10.422 10.791 10.319 11.1
Accumulated Depreciation, Total -8.049 -7.664 -9.322 -8.344 -7.426
Goodwill, Net 2.926 2.926 2.926 2.926 2.926
Intangibles, Net 0 0 0 0 0
Other Long Term Assets, Total 0.22 0.231 0.433 0.308 0.334
Total Current Liabilities 13.844 11.223 25.779 15.967 13.37
Accounts Payable 3.309 2.651 5.332 5.953 5.109
Accrued Expenses 6.619 5.771 3.79 6.133 4.689
Notes Payable/Short Term Debt 0 0 13.466 0 0
Current Port. of LT Debt/Capital Leases 0
Other Current Liabilities, Total 3.916 2.801 3.191 3.881 3.572
Total Liabilities 30.076 30.997 27.505 27.427 13.724
Total Long Term Debt 13.603 16.186 0 10.836 0
Capital Lease Obligations
Deferred Income Tax 0.078 0.077 0.104
Other Liabilities, Total 2.629 3.588 1.648 0.547 0.25
Total Equity 25.208 10.028 4.342 11.089 29.26
Common Stock 0.154 0.098 0.031 0.021 0.102
Additional Paid-In Capital 293.177 261.573 235.594 228.43 224.91
Retained Earnings (Accumulated Deficit) -267.534 -251.376 -234.547 -216.692 -195.176
Other Equity, Total -0.623 -0.385 -0.701 -0.67 -0.576
Total Liabilities & Shareholders’ Equity 55.284 41.025 31.847 38.516 42.984
Total Common Shares Outstanding 6.14704 3.90654 1.25756 0.8429 0.81872
Long Term Debt 13.603 16.186 0 10.836
Redeemable Preferred Stock 3.965
Total Preferred Shares Outstanding 0 0 0.07
Preferred Stock - Non Redeemable, Net 0.034 0.118
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 43.783 49.354 52.654 55.34 57.749
Cash and Short Term Investments 21.606 29.972 33.385 37.081 40.842
Cash & Equivalents 21.606 29.972 33.385 37.081 40.842
Total Receivables, Net 5.18 4.238 3.637 3.819 3.266
Accounts Receivable - Trade, Net 5.18 4.238 3.637 3.819 3.266
Total Inventory 14.611 12.929 14.062 12.715 11.877
Prepaid Expenses 2.183 2.012 1.366 1.521 1.56
Other Current Assets, Total 0.203 0.203 0.204 0.204 0.204
Total Assets 50.242 55.284 58.514 61.249 63.484
Property/Plant/Equipment, Total - Net 3.302 2.784 2.712 2.758 2.583
Property/Plant/Equipment, Total - Gross 11.469 10.833 10.643 10.587 10.324
Accumulated Depreciation, Total -8.167 -8.049 -7.931 -7.829 -7.741
Goodwill, Net 2.926 2.926 2.926 2.926 2.926
Other Long Term Assets, Total 0.231 0.22 0.222 0.225 0.226
Total Current Liabilities 13.112 13.844 13.457 12.719 11.27
Accounts Payable 4.643 3.309 3.597 3.502 3.072
Accrued Expenses 5.167 6.619 4.929 5.174 5.386
Notes Payable/Short Term Debt 0 0 0 0.7 0
Other Current Liabilities, Total 3.302 3.916 3.531 3.343 2.812
Total Liabilities 29.642 30.076 28.192 27.993 29.968
Total Long Term Debt 13.666 13.603 12.114 12.703 16.295
Long Term Debt 13.666 13.603 12.114 12.703 16.295
Other Liabilities, Total 2.864 2.629 2.621 2.571 2.403
Total Equity 20.6 25.208 30.322 33.256 33.516
Preferred Stock - Non Redeemable, Net 0 0.034 0.034 0.035 0.036
Common Stock 0.155 0.154 0.153 0.151 0.149
Additional Paid-In Capital 293.419 293.177 292.948 292.517 292.141
Retained Earnings (Accumulated Deficit) -272.31 -267.534 -262.255 -258.979 -258.277
Other Equity, Total -0.664 -0.623 -0.558 -0.468 -0.533
Total Liabilities & Shareholders’ Equity 50.242 55.284 58.514 61.249 63.484
Total Common Shares Outstanding 6.176 6.14704 6.13108 6.04944 5.97652
Total Preferred Shares Outstanding 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.4
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -16.158 -16.829 -17.855 -21.516 -16.851
Cash From Operating Activities -16.71 -12.795 -12.746 -14.147 -18.412
Cash From Operating Activities 0.4 0.499 0.982 0.945 1.203
Deferred Taxes 0.007 -0.027 -0.694
Non-Cash Items 0.985 1.781 5.228 6.46 3.333
Cash Taxes Paid 0.171 0.022 0.035 0.044 0.164
Cash Interest Paid 1.771 1.881 1.784 0.023 0.001
Changes in Working Capital -1.937 1.754 -1.108 -0.009 -5.403
Cash From Investing Activities -0.707 -0.096 -0.207 -0.522 -0.747
Capital Expenditures -0.707 -0.096 -0.207 -0.558 -0.747
Other Investing Cash Flow Items, Total 0 0.036 0
Cash From Financing Activities 29.954 24.349 10.721 11.235 21.618
Financing Cash Flow Items -1.135 -3.049 -0.954 -1.222 0
Issuance (Retirement) of Stock, Net 31.114 24.958 9.175 0.003 21.764
Issuance (Retirement) of Debt, Net -0.025 2.44 2.5 12.454 -0.146
Foreign Exchange Effects -0.238 0.317 -0.023 -0.106 0.262
Net Change in Cash 12.299 11.775 -2.255 -3.54 2.721
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -4.776 -16.158 -10.879 -7.603 -6.901
Cash From Operating Activities -8.021 -16.71 -13.606 -10.008 -6.499
Cash From Operating Activities 0.117 0.4 0.281 0.176 0.085
Deferred Taxes 0
Non-Cash Items 0.42 0.985 -1.035 -1.461 1.118
Cash Taxes Paid 0.026 0.171 0.154 0.13 0.01
Cash Interest Paid 0.377 1.771 1.328 0.886 0.448
Changes in Working Capital -3.782 -1.937 -1.973 -1.12 -0.801
Cash From Investing Activities -0.304 -0.707 -0.396 -0.311 -0.008
Capital Expenditures -0.304 -0.707 -0.396 -0.311 -0.008
Cash From Financing Activities 0 29.954 29.886 29.811 29.825
Financing Cash Flow Items 0 -1.135 -0.006 -0.006 -0.006
Issuance (Retirement) of Stock, Net 0 31.114 29.917 29.841 29.831
Foreign Exchange Effects -0.041 -0.238 -0.171 -0.083 -0.148
Net Change in Cash -8.366 12.299 15.713 19.409 23.17
Issuance (Retirement) of Debt, Net -0.025 -0.025 -0.024

Start a global, multi-asset portfolio with an award-winning platform

Trade now Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

BIOLASE Company profile

BIOLASE (BIOL) is a medical device company that manufactures dental laser systems. In 2012 the company changed its name from BIOLASE Technology to BIOLASE.

Founded in 1984, BIOLASE is headquartered in California. Its proprietary dental laser systems enable dentists to perform minimally invasive dental procedures.

Biolase’s Waterlase all-tissue dental laser systems can be used for cutting soft and hard tissues, and other micro-surgeries in soft tissues, pain therapy, teeth whitening and cosmetic procedures. Additionally, the Waterlase Express system minimises water usage by a significant level, and has the flexibility to treat infections like peri-implantitis and other periodontal diseases. 

Along with the laser system, BIOLASE also sells products and accessories such as teeth whitening gel kits, flexible fibres and hand pieces.

The company went public on the Nasdaq stock exchange in 1993. BIOLASE, Inc. stock trades under the ticker symbol BIOL. 

You can follow the BIOL share value and price chart  live on Capital.com.

Industry: Advanced Medical Equipment & Technology (NEC)

27042 Towne Centre Drive
Suite 270
FOOTHILL RANCH
CALIFORNIA 92610
US

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

26,996.15 Price
-0.310% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Oil - Crude

73.41 Price
+0.590% 1D Chg, %
Long position overnight fee -0.0180%
Short position overnight fee -0.0039%
Overnight fee time 21:00 (UTC)
Spread 0.03

US100

12,638.90 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0018%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

1,951.71 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0180%
Short position overnight fee 0.0097%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading